首页 > 市场调查报告书 > 製药

再生医学细胞疗法

市场调查报告书

商品编码

1578296

全球自体细胞治疗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Autologous Cell Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年09月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球自体细胞治疗市场需求预计将从 2023 年的 48.6 亿美元达到近 307.1 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 22.74%。

自体细胞疗法（ACT）是一种利用个别细胞治疗各种疾病的新型疗法。此疗法利用在体外培养的患者细胞，细胞数量在体外扩增并重新引入体内。此疗法可确保减少副作用，降低生物不相容性、与移植物相关的疾病传播以及全身免疫反应和疾病的风险。治疗可以有两种类型：自体干细胞疗法和自体细胞免疫疗法。来自骨髓表皮或其他来源的细胞用于细胞培养和扩增。自体疗法用于治疗癌症、肌肉骨骼疾病、血液疾病和美容治疗。医院和研究中心正在增加使用自体疗法来治疗患者。

市场动态

癌症、神经系统疾病和自体免疫疾病的日益普及是推动自体治疗市场的主要因素。副作用减少和其他疾病传播风险降低等因素正在推动市场发展。此外，细胞培养研发的增加以及政府在新型创新疗法方面的措施正在提振全球市场。在全球COVID-19大流行期间，由于整体医疗保健市场的成长以及细胞培养疗法研发的不断增加，自体治疗市场预计将经历稳定但倾斜的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球自体细胞治疗市场的各个细分市场进行了包容性评估。自体细胞治疗产业的成长和趋势为这项研究提供了整体方法。

市场区隔

自体细胞治疗市场报告的这一部分提供了国家和地区层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按申请

癌症
神经退化性疾病
心血管疾病
自体免疫疾病
骨科
伤口癒合
其他的

按来源

骨髓
表皮
间质干细胞
造血干细胞
软骨细胞
其他的

按最终用途

医院和诊所
门诊中心
学术与研究
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲自体细胞治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。自体细胞治疗市场的主要参与者包括 BrainStorm Cell Therapeutics、Holostem Terapie Avanzate、SRL、Pharmicell Co. Inc、Opexa Therapeutics、Caladrius Biosciences Inc、US Stem Cell Inc、Lonza、Bristol Myers Squibb、诺华、Autoego Therapeutics、T Science 、康宁公司、Bio Elpida、Vericel Corporation、Catalent Inc、Sartorius AG。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：自体细胞治疗公司的竞争格局

自体细胞治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
BrainStorm Cell Therapeutics

公司概况
公司收入
产品
最新动态

Holostem Terapie Avanzate SRL

公司概况
公司收入
产品
最新动态

Sartorius AG

公司概况
公司收入
产品
最新动态

Pharmicell Co. Inc

公司概况
公司收入
产品
最新动态

Opexa Therapeutics

公司概况
公司收入
产品
最新动态

Caladrius Biosciences Inc

公司概况
公司收入
产品
最新动态

US Stem Cell Inc

公司概况
公司收入
产品
最新动态

Lonza

公司概况
公司收入
产品
最新动态

Bristol Myers Squibb

公司概况
公司收入
产品
最新动态

Novartis

公司概况
公司收入
产品
最新动态

Autolus Therapeutics

公司概况
公司收入
产品
最新动态

Tego Science

公司概况
公司收入
产品
最新动态

Corning Incorporated

公司概况
公司收入
产品
最新动态

Bio Elpida

公司概况
公司收入
产品
最新动态

Vericel Corporation

公司概况
公司收入
产品
最新动态

Catalent Inc

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR11212590

The global demand for Autologous Cell Therapy Market is presumed to reach the market size of nearly USD 30.71 Billion by 2032 from USD 4.86 Billion in 2023 with a CAGR of 22.74% under the study period 2024-2032.

Autologous cell therapy (ACT) is a novel therapy that uses an individual's cells to treat various diseases. The therapy utilizes the patient's cells, which are cultured outside the body, the cell number is expanded in-vitro and reintroduced to the body. The therapy assures reduced side effects, reduced the risk of bio-incompatibility, disease transmission associated with graft, and systemic immunological reactions and disease. The therapy can be of two types; autologous stem cell therapy and autologous cellular immune therapies. The cells from bone marrow epidermis or other sources are utilized for cell culture and expansion. Autologous therapy is applied in the treatment of cancers, musculoskeletal disorders, blood disorders, and cosmetic treatments. Hospitals and research centers are increasing the use of autologous therapy to treat patients.

MARKET DYNAMICS

The growing prevalence of cancer, neurological disorders, and autoimmune diseases are the prime factors that are driving the autologous therapy market. The factors such as reduced side effects and reduced risk of transmission of other diseases are fuelling the market. Moreover, increasing R & D in cell culture, and government initiatives in novel innovative therapies is uplifting the global market. During the global pandemic COVID-19, the autologous therapy market is expected to experience steady but inclining growth owing to the growing overall healthcare market along with rising R & D in cell culture therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Autologous Cell Therapy. The growth and trends of Autologous Cell Therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Autologous Cell Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Cancer
Neurodegenerative Disorders
Cardiovascular Disorders
Autoimmune Disorders
Orthopedics
Wound Healing
Others

By Source

Bone Marrow
Epidermis
Mesenchymal Stem Cells
Haematopoietic Stem Cells
Chondrocytes
Others

By End-use

Hospitals & Clinics
Ambulatory Centers
Academics & Research
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Autologous Cell Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Autologous Cell Therapy market include BrainStorm Cell Therapeutics, Holostem Terapie Avanzate, S.R.L, Pharmicell Co. Inc, Opexa Therapeutics, Caladrius Biosciences Inc, U.S. Stem Cell Inc, Lonza, Bristol Myers Squibb, Novartis, Autolus Therapeutics, Tego Science, Corning Incorporated, Bio Elpida, Vericel Corporation, Catalent Inc, Sartorius AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. AUTOLOGOUS CELL THERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Source
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data Analysis By Application
5.3. Cancer Historic and Forecast Sales By Regions
5.4. Neurodegenerative Disorders Historic and Forecast Sales By Regions
5.5. Cardiovascular Disorders Historic and Forecast Sales By Regions
5.6. Autoimmune Disorders Historic and Forecast Sales By Regions
5.7. Orthopedics Historic and Forecast Sales By Regions
5.8. Wound Healing Historic and Forecast Sales By Regions
5.9. Others Historic and Forecast Sales By Regions

6. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY SOURCE

6.1. Overview By Source
6.2. Historical and Forecast Data Analysis By Source
6.3. Bone Marrow Historic and Forecast Sales By Regions
6.4. Epidermis Historic and Forecast Sales By Regions
6.5. Mesenchymal Stem Cells Historic and Forecast Sales By Regions
6.6. Haematopoietic Stem Cells Historic and Forecast Sales By Regions
6.7. Chondrocytes Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY END-USE

7.1. Overview By End-use
7.2. Historical and Forecast Data Analysis By End-use
7.3. Hospitals & Clinics Historic and Forecast Sales By Regions
7.4. Ambulatory Centers Historic and Forecast Sales By Regions
7.5. Academics & Research Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE AUTOLOGOUS CELL THERAPY COMPANIES

9.1. Autologous Cell Therapy Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF AUTOLOGOUS CELL THERAPY INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. BrainStorm Cell Therapeutics
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Holostem Terapie Avanzate S.R.L
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Sartorius AG
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Pharmicell Co. Inc
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Opexa Therapeutics
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Caladrius Biosciences Inc
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. U.S. Stem Cell Inc
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Lonza
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Bristol Myers Squibb
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Novartis
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Autolus Therapeutics
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Tego Science
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Corning Incorporated
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. Bio Elpida
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Vericel Corporation
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. Catalent Inc
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments